Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Squamous Cell Carcinoma 8 Esophageal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 2 Uterine Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Neoplasm Metastasis 1 Mouth Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Carboplatin 358 Pemetrexed 275 Cisplatin 229 Paclitaxel 212 Docetaxel 205 Gemcitabine 160 Erlotinib Hydrochloride 150 Bevacizumab 132 pembrolizumab 128 Radiotherapy 112 Nivolumab 88 durvalumab 84 Drug Therapy 84 osimertinib 81 atezolizumab 58 Vinorelbine 53 Gefitinib 53 Radiosurgery 49 Cetuximab 39 Taxes 37 130-nm albumin-bound paclitaxel 35 Ipilimumab 34 anlotinib 33 Surgical Procedures, Operative 33 Magnetic Resonance Spectroscopy 33 Etoposide 30 Albumin-Bound Paclitaxel 29 tislelizumab 27 icotinib 27 Specimen Handling 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Non-Small-Cell Lung × TP protocol × Clear all

NCT00680940 2012-08-07

NSCLC

Cadila Pharnmaceuticals

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡